Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

por Poon, Evon, Liang, Tong, Jamin, Yann, Walz, Susanne, Kwok, Colin, Hakkert, Anne, Barker, Karen, Urban, Zuzanna, Thway, Khin, Zeid, Rhamy, Hallsworth, Albert, Box, Gary, Ebus, Marli E., Licciardello, Marco P., Sbirkov, Yordan, Lazaro, Glori, Calton, Elizabeth, Costa, Barbara M., Valenti, Melanie, De Haven Brandon, Alexis, Webber, Hannah, Tardif, Nicolas, Almeida, Gilberto S., Christova, Rossitza, Boysen, Gunther, Richards, Mark W., Barone, Giuseppe, Ford, Anthony, Bayliss, Richard, Clarke, Paul A., De Bono, Johann, Gray, Nathanael S., Blagg, Julian, Robinson, Simon P., Eccles, Suzanne A., Zheleva, Daniella, Bradner, James E., Molenaar, Jan, Vivanco, Igor, Eilers, Martin, Workman, Paul, Lin, Charles Y., Chesler, Louis
Publicado 2020